send link to app

Oral chemotherapies app for iPhone and iPad


4.6 ( 2096 ratings )
Health & Fitness Medical
Developer: Brouard Benoit
9.99 USD
Current version: 1.1, last update: 7 years ago
First release : 28 Jan 2015
App size: 3.18 Mb

New targeted agents have the same frequency and severity of toxicities as traditional cytotoxic agents, with the difference being the nature of the toxic effects. Thus, the classical chemotherapy toxicities (vomiting, myelosuppression, mucositis, nausea, and alopecia) have been generally replaced by endocrine, dermatologic, vascular, coagulation, immunologic, ocular, and pulmonary toxicities. These toxicities need to be recognized, prevented, and optimally managed.

AKPO was created by Mr. Benoît Brouard PharmD and Mrs. Pascale Bardo PharmD under the medico-scientific supervision of Mr. Stéphane Vignot MD Oncologist and Head of Oncology and Service hematology to Chârtres Hospitals.

AKPO provides an overview of these toxicities, associated with new targeted agents, and relevant informations for the management of patients.

These informations are based on current recommendations of international scientific publications.


The interface of the application is designed to facilitate access to content. It is divided into four tabs:

• Search
• Adverse events
• Oral targeted therapies
• Informations


The first three tabs will be used to access to the data in the application.

The "Search" tab allows the user to perform a search using the terms of his choice. The results are then presented and classified dynamically in the search field.

The "Adverse events" tab gives access to a list of toxicities induced by anti-cancer agents orally. All of these toxicities are listed in alphabetical order according to the classes of toxicities which they belong.

The "Oral targeted therapies" tab: provides access to information similar to the previous tab. The user has access to the list of drugs in the application.


AKPO is an application developed by Healthcare Providers for Healthcare Providers.